Singh Rishi P, Habbu Karishma A, Bedi Rumneek, Silva Fabiana Q, Ehlers Justis P, Schachat Andrew P, Sears Jonathan E, Srivastava Sunil K, Kaiser Peter K, Yuan Alex
Cole Eye Institute, Cleveland Clinic, Cleveland, Ohio, USA.
Br J Ophthalmol. 2017 Oct;101(10):1340-1345. doi: 10.1136/bjophthalmol-2016-309747. Epub 2017 Mar 3.
To compare anti-vascular endothelial growth factor (VEGF) treatment outcomes for macular oedema (ME) secondary to retinal vein occlusion (RVO) based on vitreoretinal interface (VRI) status.
This retrospective case series includes treatment-naive eyes diagnosed with RVO and treated with anti-VEGF injections. Eyes were stratified based on international VRI classification schema at baseline into three groups-vitreomacular traction (group A), no posterior vitreous detachment (PVD) (group B) and PVD without vitreomacular attachment (group C). Fifty-two eyes were identified based on inclusion/exclusion criteria. The primary endpoint was change in central subfield thickness (CST) on optical coherence tomography at 6 months.
There were no statistically significant differences in baseline characteristics of patients with RVO when stratified by VRI subgroups. After 6 months of treatment, there was no statistically significant difference in the change in CST from baseline between VRI cohorts (p=0.11). There was a trend demonstrating the greatest improvement in CST in eyes in group A compared with eyes in groups B and C (-224.13 μm, -160.88 μm and -50.92 μm, respectively, p=0.11 between cohorts). Mean change in logarithm of the minimum angle of resolution visual acuity from baseline to month 6 in group A compared with groups B and C was -0.25, -0.14 and -0.13, respectively (p=0.64 between cohorts).
We did not identify an association between VRI status and treatment outcomes with anti-VEGF agents for ME secondary to RVO.
基于玻璃体视网膜界面（VRI）状态比较抗血管内皮生长因子（VEGF）治疗视网膜静脉阻塞（RVO）继发黄斑水肿（ME）的效果。
本回顾性病例系列研究纳入初治的RVO患者，接受抗VEGF注射治疗。根据国际VRI分类标准，将患者基线时的眼睛分为三组：玻璃体黄斑牵拉（A组）、无玻璃体后脱离（PVD）（B组）和有PVD但无玻璃体黄斑附着（C组）。根据纳入/排除标准确定52只眼睛。主要终点是治疗6个月时光学相干断层扫描测量的中心子野厚度（CST）变化。
按VRI亚组分层时，RVO患者的基线特征无统计学显著差异。治疗6个月后，VRI各队列间CST自基线的变化无统计学显著差异（p = 0.11）。有趋势表明，A组眼睛的CST改善最大，与B组和C组眼睛相比，分别为-224.13μm、-160.88μm和-50.92μm（队列间p = 0.11）。A组与B组和C组相比，从基线到第6个月最小分辨角视力对数的平均变化分别为-0.25、-0.14和-0.13（队列间p = 0.64）。
我们未发现VRI状态与抗VEGF药物治疗RVO继发ME的疗效之间存在关联。
